Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes

血糖性 2型糖尿病 内科学 临床终点 随机对照试验 安慰剂 糖尿病 物理疗法 医学 胰岛素 内分泌学 替代医学 病理
作者
Linong Ji,Jianhua Ma,Yujin Ma,Zhifeng Cheng,Shenglian Gan,Guoyue Yuan,Dexue Liu,Sheli Li,Yu Liu,Xia Xue,Jie Bai,Kun Wang,Hanqing Cai,Shu Li,Kui Liu,Meng Yu,Liping Liu
出处
期刊:JAMA network open [American Medical Association]
卷期号:8 (3): e2462185-e2462185 被引量:40
标识
DOI:10.1001/jamanetworkopen.2024.62185
摘要

Importance: Few of the available therapies for type 2 diabetes (T2D) comprehensively address disease burden beyond glycemic control. Examining whether berberine ursodeoxycholate (HTD1801), a first-in-class gut-liver anti-inflammatory metabolic modulator, has the potential to treat the core aspects of metabolic disease is important. Objective: To assess the safety and efficacy of HTD1801 in patients with T2D that is inadequately controlled with diet and exercise. Design, Setting, and Participants: This phase 2 double-blind, placebo-controlled, 12-week randomized clinical trial, conducted in China between March 2022 and January 2023, included patients with T2D who underwent 8 or more weeks of diet and exercise, had a hemoglobin A1c (HbA1c) level of 7.0% to 10.5%, and had a fasting plasma glucose (FPG) level less than 250.5 mg/dL. Interventions: Patients were randomized 1:1:1 to placebo (n = 38), HTD1801 500 mg twice daily (n = 37), and HTD1801 1000 mg twice daily (n = 38). Main Outcomes and Measures: The primary end point was the HbA1c level change from baseline to week 12. Secondary end points included glycemic, hepatic, and cardiometabolic parameters. The primary end point was analyzed using a mixed-effects model for repeated measures, with the HbA1c level change from baseline as the dependent variable. Treatment group, measurement time point, and interaction between treatment group and measurement time point were independent variables. Results: The study included 113 patients with T2D (mean [SD] age, 54.3 [10.6] years; 72 male [63.7%]) who were randomized. Among these patients, the mean (SD) HbA1c level was 8.2% (0.8%); body mass index, 25.5 (3.7), calculated as weight in kilograms divided by height in meters squared; and FPG level, 160.7 (38.3) mg/dL. Baseline disease severity was balanced across treatment groups. The primary end point was achieved with significant dose-dependent reductions in the HbA1c level in both HTD1801 groups compared with the placebo group. The least-squares mean difference in the HbA1c level at week 12 was -0.4% (95% CI, -0.79% to -0.03%; P = .04) for the 500-mg group and -0.7% (95% CI, -1.10% to -0.35%; P < .001) for the 1000-mg group compared with the placebo group. HbA1c level reductions were paralleled with mean (SD) improvements in the FPG level in both the 500-mg group (-13.0 [38.2] mg/dL) and the 1000-mg group (-18.4 [21.8] mg/dL) groups. Reductions were observed in lipids and markers of liver injury in the 1000-mg group. HTD1801 was safe and well tolerated, with 110 patients (97.3%) completing the study. Treatment-emergent adverse events, generally mild, occurred in 59 patients (52.2%) overall. One patient (in the 500-mg group) experienced a serious adverse event of retinal hemorrhage, which was unlikely related to treatment. No patients discontinued due to an adverse event. Conclusions and Relevance: In this placebo-controlled randomized clinical trial, treatment with HTD1801 resulted in significant reductions in the HbA1c level and improvements in key cardiometabolic and liver parameters. HTD1801 was safe and well tolerated. These findings are being confirmed in ongoing phase 3 studies. The effects demonstrated by HTD1801 support an oral treatment option for T2D and its comorbidities. Trial Registration: ClinicalTrials.gov Identifier: NCT06411275.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
LSQ47发布了新的文献求助10
刚刚
张维为完成签到,获得积分10
1秒前
专注的隶完成签到,获得积分10
1秒前
喜悦成威发布了新的文献求助20
1秒前
阿猫发布了新的文献求助10
2秒前
舒适的严青完成签到,获得积分10
3秒前
小郭发布了新的文献求助10
3秒前
3秒前
小桔啊完成签到 ,获得积分10
5秒前
彭于晏的应助被杭世立采纳,获得10
5秒前
chen555完成签到,获得积分10
5秒前
6秒前
典雅的羿完成签到 ,获得积分10
6秒前
6秒前
7秒前
7秒前
大气水杯完成签到 ,获得积分10
7秒前
雪白老头发布了新的文献求助10
8秒前
yinhao完成签到,获得积分20
9秒前
10秒前
xf完成签到,获得积分10
11秒前
11秒前
luluyuan2010发布了新的文献求助30
11秒前
嘻嘻嘻发布了新的文献求助10
11秒前
12秒前
李健的小迷弟的应助被Jian采纳,获得10
12秒前
12秒前
clwlf发布了新的文献求助10
12秒前
科研小郭完成签到,获得积分20
13秒前
彭于晏的应助被阿猫采纳,获得10
13秒前
MANDY的应助被CJB采纳,获得10
13秒前
苏七完成签到,获得积分0
14秒前
lkh发布了新的文献求助10
14秒前
机灵南风完成签到,获得积分10
14秒前
慕豁发布了新的文献求助20
15秒前
kk发布了新的文献求助10
15秒前
16秒前
wuhuarou完成签到,获得积分20
16秒前
Esaaion发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190845
求助须知:如何正确求助?哪些是违规求助? 9577920
关于积分的说明 21855571
捐赠科研通 7789983
什么是DOI,文献DOI怎么找? 3436475
关于科研通互助平台的介绍 2560308
邀请新用户注册赠送积分活动 2483197